{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:52:32Z","timestamp":1754153552664,"version":"3.41.2"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"DOI":"10.7759\/cureus.88561","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:56:13Z","timestamp":1753253773000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management"],"prefix":"10.7759","author":[{"given":"Abdul Hamid","family":"Zargar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayagopal Pathiyil","family":"Balagopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpandev","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijit","family":"Taraphder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Dani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilakshi","family":"Deka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onkar C","family":"Swami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9985836","article-title":"Sodium-glucose cotransporter-2 inhibitors and cardiovascular protection among patients with type 2 diabetes mellitus: a systematic review","volume":"2024","author":"Yankah RK","year":"2024","unstructured":"Yankah RK, Anku EK, Eligar V. Sodium-glucose cotransporter-2 inhibitors and cardiovascular protection among patients with type 2 diabetes mellitus: a systematic review. J Diabetes Res. 2024, 2024:9985836. 10.1155\/2024\/9985836","journal-title":"J Diabetes Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108078","article-title":"Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"162","author":"Sinclair A","year":"2020","unstructured":"Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, Williams R. Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2020, 162:108078. 10.1016\/j.diabres.2020.108078","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018, 34:575-84. 10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22932-4","article-title":"The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study","volume":"12","author":"Eliasson B","year":"2022","unstructured":"Eliasson B, Lyngfelt L, Str\u00f6mblad SO, Franz\u00e9n S, Eeg-Olofsson K. The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study. Sci Rep. 2022, 12:17950. 10.1038\/s41598-022-22932-4","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.07.029","article-title":"Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes","volume":"5","author":"Cabrera CS","year":"2020","unstructured":"Cabrera CS, Lee AS, Olsson M, et al.. Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. Kidney Int Rep. 2020, 5:1651-60. 10.1016\/j.ekir.2020.07.029","journal-title":"Kidney Int Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15128","article-title":"eGFR slope as predictor of mortality in heart failure patients","volume":"12","author":"Verstreken S","year":"2025","unstructured":"Verstreken S, Beles M, Oeste CL, et al.. eGFR slope as predictor of mortality in heart failure patients. ESC Heart Fail. 2025, 12:1217-26. 10.1002\/ehf2.15128","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15181","article-title":"Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes","volume":"25","author":"Bell DS","year":"2023","unstructured":"Bell DS, McGill JB, Jerkins T. Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes. Diabetes Obes Metab. 2023, 25:2795-804. 10.1111\/dom.15181","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01038-6","article-title":"Prevalence of cardiovascular and renal co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study","volume":"12","author":"Al-Ozairi E","year":"2021","unstructured":"Al-Ozairi E, Jallo MK, Hafidh K, et al.. Prevalence of cardiovascular and renal co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study. Diabetes Ther. 2021, 12:1193-207. 10.1007\/s13300-021-01038-6","journal-title":"Diabetes Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele CE","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al.. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023, 148:1606-35. 10.1161\/CIR.0000000000001184","journal-title":"Circulation"},{"article-title":"IDF Diabetes Atlas 11th Edition","year":"2025","key":"ref10","unstructured":"IDF Diabetes Atlas 11th Edition. Magliano DJ, Boyko EJ, Genitsaridi I, Piemonte L, Riley P, Salpea P (ed). International Diabetes Federation, Amsterdam, Netherlands; 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson TR","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018, 17:83. 10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1168291","article-title":"Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus","volume":"32","author":"Iglay K","year":"2016","unstructured":"Iglay K, Hannachi H, Joseph Howie P, et al.. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016, 32:1243-52. 10.1185\/03007995.2016.1168291","journal-title":"Curr Med Res Opin"},{"key":"ref13","article-title":"Indian guidance on cardiovascular and renal comorbidity management in type-2 diabetes mellitus","volume":"7","author":"Das AK","year":"2018","unstructured":"Das AK, Unnikrishnan AG, Saboo B, Mohan V, Vijay V. Indian guidance on cardiovascular and renal comorbidity management in type-2 diabetes mellitus. J Assoc Physicians India. 2018, 7:","journal-title":"J Assoc Physicians India"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.58","article-title":"Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease","volume":"88","author":"Anand S","year":"2015","unstructured":"Anand S, Shivashankar R, Ali MK, et al.. Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. Kidney Int. 2015, 88:178-85. 10.1038\/ki.2015.58","journal-title":"Kidney Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.396","article-title":"Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes","volume":"85","author":"Wang Y","year":"2014","unstructured":"Wang Y, Katzmarzyk PT, Horswell R, Zhao W, Johnson J, Hu G. Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Kidney Int. 2014, 85:1192-9. 10.1038\/ki.2013.396","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02234-2","article-title":"Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals","volume":"20","author":"Zhang R","year":"2022","unstructured":"Zhang R, Mamza JB, Morris T, et al.. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med. 2022, 20:63. 10.1186\/s12916-022-02234-2","journal-title":"BMC Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.986186","article-title":"Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: a system review and network meta-analysis","volume":"13","author":"Tian L","year":"2022","unstructured":"Tian L, Ai S, Zheng H, et al.. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: a system review and network meta-analysis. Front Pharmacol. 2022, 13:986186. 10.3389\/fphar.2022.986186","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann JF","year":"2017","unstructured":"Mann JF, \u00d8rsted DD, Brown-Frandsen K, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017, 377:839-48. 10.1056\/NEJMoa1616011","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein HC","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al.. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021, 385:896-907. 10.1056\/NEJMoa2108269","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv111","article-title":"Vascular calcification in chronic kidney disease: an update","volume":"31","author":"Schlieper G","year":"2016","unstructured":"Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant. 2016, 31:31-9. 10.1093\/ndt\/gfv111","journal-title":"Nephrol Dial Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.22265\/acnef.7.1.356","article-title":"[The cardiorenal continuum: a proposal for the prevention of cardiovascular and renal diseases] (Article in Spanish)","volume":"7","author":"Maimi PA","year":"2020","unstructured":"Maimi PA, Rodulfo IA. [The cardiorenal continuum: a proposal for the prevention of cardiovascular and renal diseases] (Article in Spanish). Rev Colomb Nefrol. 2020, 7:60-9. 10.22265\/acnef.7.1.356","journal-title":"Rev Colomb Nefrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-021-02037-7","article-title":"Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches","volume":"99","author":"D\u00fcsing P","year":"2021","unstructured":"D\u00fcsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, Jansen F. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med (Berl). 2021, 99:335-48. 10.1007\/s00109-021-02037-7","journal-title":"J Mol Med (Berl)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.835","article-title":"Outcomes of asymptomatic left ventricular dysfunction in the patient with or without type 2 diabetic mellitus","volume":"44","author":"Ling L","year":"2023","unstructured":"Ling L, Sung SH. Outcomes of asymptomatic left ventricular dysfunction in the patient with or without type 2 diabetic mellitus. Eur Heart J. 2023, 44:655-835. 10.1093\/eurheartj\/ehad655.835","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00747-4","article-title":"Diagnosis of cardiovascular disease in patients with chronic kidney disease","volume":"19","author":"Zoccali C","year":"2023","unstructured":"Zoccali C, Mark PB, Sarafidis P, et al.. Diagnosis of cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2023, 19:733-46. 10.1038\/s41581-023-00747-4","journal-title":"Nat Rev Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association","volume":"45","author":"Pop-Busui R","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, et al.. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022, 45:1670-90. 10.2337\/dci22-0014","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14019","article-title":"Higher BNP\/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis","volume":"9","author":"Hendricks S","year":"2022","unstructured":"Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. Higher BNP\/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. ESC Heart Fail. 2022, 9:3198-209. 10.1002\/ehf2.14019","journal-title":"ESC Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008032","article-title":"Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease","volume":"7","author":"Kraus D","year":"2018","unstructured":"Kraus D, von Jeinsen B, Tzikas S, et al.. Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease. J Am Heart Assoc. 2018, 7:e008032. 10.1161\/JAHA.117.008032","journal-title":"J Am Heart Assoc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2023.05.002","article-title":"Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society","volume":"79","author":"Yeung AM","year":"2023","unstructured":"Yeung AM, Huang J, Pandey A, et al.. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society. Prog Cardiovasc Dis. 2023, 79:65-79. 10.1016\/j.pcad.2023.05.002","journal-title":"Prog Cardiovasc Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00235-1","article-title":"Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study","volume":"4","author":"Tromp J","year":"2022","unstructured":"Tromp J, Seekings PJ, Hung CL, et al.. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Lancet Digit Health. 2022, 4:e46-54. 10.1016\/S2589-7500(21)00235-1","journal-title":"Lancet Digit Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0216-8","article-title":"Deep learning interpretation of echocardiograms","volume":"3","author":"Ghorbani A","year":"2020","unstructured":"Ghorbani A, Ouyang D, Abid A, et al.. Deep learning interpretation of echocardiograms. NPJ Digit Med. 2020, 3:10. 10.1038\/s41746-019-0216-8","journal-title":"NPJ Digit Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01403-2","article-title":"Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control","volume":"11","author":"Iwao M","year":"2021","unstructured":"Iwao M, Tanaka R, Suzuki Y, et al.. Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control. Sci Rep. 2021, 11:21931. 10.1038\/s41598-021-01403-2","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen TK","year":"2019","unstructured":"Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019, 322:1294-304. 10.1001\/jama.2019.14745","journal-title":"JAMA"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-023-00243-y","article-title":"The utility of estimation of glomerular filtration rate by serum cystatin C as a predictor of diabetic kidney disease in both type I and type II diabetic patients: a single center study","volume":"35","author":"Mansour AE","year":"2023","unstructured":"Mansour AE, Abdelmoniem RO, Elbadawy AM, Ibrahim WM. The utility of estimation of glomerular filtration rate by serum cystatin C as a predictor of diabetic kidney disease in both type I and type II diabetic patients: a single center study. Egypt J Intern Med. 2023, 35:64. 10.1186\/s43162-023-00243-y","journal-title":"Egypt J Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/genes15010078","article-title":"Liquid biopsy: a new avenue for the diagnosis of kidney disease: diabetic kidney disease, renal cancer, and IgA nephropathy","volume":"15","author":"Dybiec J","year":"2024","unstructured":"Dybiec J, Fr\u0105k W, Ku\u0107mierz J, et al.. Liquid biopsy: a new avenue for the diagnosis of kidney disease: diabetic kidney disease, renal cancer, and IgA nephropathy. Genes (Basel). 2024, 15:78. 10.3390\/genes15010078","journal-title":"Genes (Basel)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2024.22.2.21","article-title":"A new era in diabetic kidney disease treatment: the four pillars and strategies to build beyond","volume":"22","author":"Han S","year":"2024","unstructured":"Han S, Kim S. A new era in diabetic kidney disease treatment: the four pillars and strategies to build beyond. Electrolyte Blood Press. 2024, 22:21-8. 10.5049\/EBP.2024.22.2.21","journal-title":"Electrolyte Blood Press"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102:S1-S127. 10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire DK","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021, 6:148-58. 10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al.. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021, 384:129-39. 10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:435-47. 10.1016\/j.jacc.2019.11.036","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.06.017","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"9","author":"McMurray JJ","year":"2021","unstructured":"McMurray JJ, Wheeler DC, Stef\u00e1nsson BV, et al.. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021, 9:807-20. 10.1016\/j.jchf.2021.06.017","journal-title":"JACC Heart Fail"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.023","article-title":"Management of diabetes mellitus in patients with CKD: core curriculum 2022","volume":"79","author":"Hahr AJ","year":"2022","unstructured":"Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with CKD: core curriculum 2022. Am J Kidney Dis. 2022, 79:728-36. 10.1053\/j.ajkd.2021.05.023","journal-title":"Am J Kidney Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2023.100236","article-title":"Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis","volume":"17","author":"Mima A","year":"2023","unstructured":"Mima A, Gotoda H, Lee R, Murakami A, Akai R, Lee S. Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis. Metabol Open. 2023, 17:100236. 10.1016\/j.metop.2023.100236","journal-title":"Metabol Open"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen SL","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7:776-85. 10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01949-7","article-title":"Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","volume":"22","author":"Rossing P","year":"2023","unstructured":"Rossing P, Bain SC, Bosch-Traberg H, Sokareva E, Heerspink HJ, Rasmussen S, Mellbin LG. Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Cardiovasc Diabetol. 2023, 22:220. 10.1186\/s12933-023-01949-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet MH","year":"2018","unstructured":"Muskiet MH, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJ, van Raalte DH. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018, 6:859-69. 10.1016\/S2213-8587(18)30268-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-019-0476-0","article-title":"Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases","volume":"11","author":"Bashier A","year":"2019","unstructured":"Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr. 2019, 11:80. 10.1186\/s13098-019-0476-0","journal-title":"Diabetol Metab Syndr"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg LE","year":"2019","unstructured":"Clegg LE, Penland RC, Bachina S, et al.. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019, 18:138. 10.1186\/s12933-019-0942-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12010014","article-title":"Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis","volume":"12","author":"Krisanapan P","year":"2024","unstructured":"Krisanapan P, Sanpawithayakul K, Pattharanitima P, et al.. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases. 2024, 12:14. 10.3390\/diseases12010014","journal-title":"Diseases"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02132-x","article-title":"Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Gong Y","year":"2024","unstructured":"Gong Y, Bai X, Zhang D, et al.. Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2024, 23:157. 10.1186\/s12944-024-02132-x","journal-title":"Lipids Health Dis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_237_21","article-title":"Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis","volume":"25","author":"Dalui SK","year":"2021","unstructured":"Dalui SK, Chakraverty R, Yasmin N, Pattanaik S, Pandit K, Chatterjee S. Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis. Indian J Endocrinol Metab. 2021, 25:283-92. 10.4103\/ijem.ijem_237_21","journal-title":"Indian J Endocrinol Metab"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green JB","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al.. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015, 373:232-42. 10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13078","article-title":"Cardiovascular outcomes of vildagliptin in patients with type\u00a02 diabetes mellitus after acute coronary syndrome or acute ischemic stroke","volume":"11","author":"Chen DY","year":"2020","unstructured":"Chen DY, Li YR, Mao CT, et al.. Cardiovascular outcomes of vildagliptin in patients with type\u00a02 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. J Diabetes Investig. 2020, 11:110-24. 10.1111\/jdi.13078","journal-title":"J Diabetes Investig"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae385","article-title":"Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients","volume":"18","author":"Liao HW","year":"2025","unstructured":"Liao HW, Cheng CY, Chen HY, Chen JY, Pan HC, Huang TM, Wu VC. Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients. Clin Kidney J. 2025, 18:sfae385. 10.1093\/ckj\/sfae385","journal-title":"Clin Kidney J"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa225","article-title":"Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial","volume":"14","author":"Wanner C","year":"2021","unstructured":"Wanner C, Cooper ME, Johansen OE, et al.. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Clin Kidney J. 2021, 14:226-36. 10.1093\/ckj\/sfaa225","journal-title":"Clin Kidney J"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.12.029","article-title":"Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study","volume":"181","author":"Chen DY","year":"2015","unstructured":"Chen DY, Wang SH, Mao CT, et al.. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol. 2015, 181:200-6. 10.1016\/j.ijcard.2014.12.029","journal-title":"Int J Cardiol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark BA","year":"2019","unstructured":"Bergmark BA, Bhatt DL, McGuire DK, et al.. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Circulation. 2019, 140:1004-14. 10.1161\/CIRCULATIONAHA.119.040144","journal-title":"Circulation"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52078-4","article-title":"Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study","volume":"14","author":"Yi Y","year":"2024","unstructured":"Yi Y, Kwon EJ, Yun G, et al.. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study. Sci Rep. 2024, 14:2081. 10.1038\/s41598-024-52078-4","journal-title":"Sci Rep"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0110-2","article-title":"DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study","volume":"13","author":"Nakamura K","year":"2014","unstructured":"Nakamura K, Oe H, Kihara H, et al.. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014, 13:110. 10.1186\/s12933-014-0110-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.599545","article-title":"Insulin therapy is associated with an increased risk of carotid plaque in type 2 diabetes: a real-world study","volume":"8","author":"Ke JF","year":"2021","unstructured":"Ke JF, Wang JW, Zhang ZH, Chen MY, Lu JX, Li LX. Insulin therapy is associated with an increased risk of carotid plaque in type 2 diabetes: a real-world study. Front Cardiovasc Med. 2021, 8:599545. 10.3389\/fcvm.2021.599545","journal-title":"Front Cardiovasc Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.559446","article-title":"Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease-a systematic review and meta-analysis","volume":"11","author":"Hu Y","year":"2020","unstructured":"Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, Fu P. Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease-a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2020, 11:559446. 10.3389\/fendo.2020.559446","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi SE","year":"2014","unstructured":"Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014, 312:2668-75. 10.1001\/jama.2014.15298","journal-title":"JAMA"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01965-0","article-title":"Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis","volume":"7","author":"Wang W","year":"2017","unstructured":"Wang W, Zhou X, Kwong JS, Li L, Li Y, Sun X. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci Rep. 2017, 7:1717. 10.1038\/s41598-017-01965-0","journal-title":"Sci Rep"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2262","article-title":"Association of renal and cardiovascular safety with DPP-4 inhibitors vs. sulfonylureas in patients with type 2 diabetes and advanced chronic kidney disease","volume":"110","author":"Yang CT","year":"2021","unstructured":"Yang CT, Lin WH, Li LJ, Ou HT, Kuo S. Association of renal and cardiovascular safety with DPP-4 inhibitors vs. sulfonylureas in patients with type 2 diabetes and advanced chronic kidney disease. Clin Pharmacol Ther. 2021, 110:464-72. 10.1002\/cpt.2262","journal-title":"Clin Pharmacol Ther"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.01.011","article-title":"Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Hansen M","year":"2017","unstructured":"Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsb\u00f8ll T, Knop FK. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications. 2017, 31:918-27. 10.1016\/j.jdiacomp.2017.01.011","journal-title":"J Diabetes Complications"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray KK","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, et al.. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024, 12:19-28. 10.1016\/S2213-8587(23)00316-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02648-1","article-title":"Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database","volume":"24","author":"Rossi A","year":"2025","unstructured":"Rossi A, Masi D, Zilich R, et al.. Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Cardiovasc Diabetol. 2025, 24:94. 10.1186\/s12933-025-02648-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1333553","article-title":"Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia","volume":"15","author":"Yen CL","year":"2024","unstructured":"Yen CL, Fan PC, Lee CC, et al.. Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia. Front Endocrinol (Lausanne). 2024, 15:1333553. 10.3389\/fendo.2024.1333553","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030768","article-title":"The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies","volume":"11","author":"Hadjivasilis A","year":"2022","unstructured":"Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies. J Clin Med. 2022, 11:768. 10.3390\/jcm11030768","journal-title":"J Clin Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29140","article-title":"A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease","volume":"14","author":"Igweonu-Nwakile EO","year":"2022","unstructured":"Igweonu-Nwakile EO, Ali S, Paul S, et al.. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus. 2022, 14:e29140. 10.7759\/cureus.29140","journal-title":"Cureus"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx566","article-title":"Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials","volume":"39","author":"Koskinas KC","year":"2018","unstructured":"Koskinas KC, Siontis GC, Piccolo R, Mavridis D, R\u00e4ber L, Mach F, Windecker S. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018, 39:1172-80. 10.1093\/eurheartj\/ehx566","journal-title":"Eur Heart J"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01283-w","article-title":"Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus","volume":"20","author":"Fischer LT","year":"2021","unstructured":"Fischer LT, Hochfellner DA, Knoll L, P\u00f6ttler T, Mader JK, Aberer F. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovasc Diabetol. 2021, 20:89. 10.1186\/s12933-021-01283-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2024.09.1090","article-title":"Inclisiran treatment for cardiovascular disease risk reduction: a systematic review and meta-analysis","volume":"34","author":"Chen YF","year":"2024","unstructured":"Chen YF, Li S, Wang MJ, Wu MY, du ZC, Wei LP. Inclisiran treatment for cardiovascular disease risk reduction: a systematic review and meta-analysis. J Coll Physicians Surg Pak. 2024, 34:1090-5. 10.29271\/jcpsp.2024.09.1090","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100127","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero AF","year":"2022","unstructured":"Cicero AF, Fogacci F, Zambon A, Toth PP, Borghi C. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am Heart J Plus. 2022, 13:100127. 10.1016\/j.ahjo.2022.100127","journal-title":"Am Heart J Plus"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad248","article-title":"Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients","volume":"39","author":"Goto H","year":"2024","unstructured":"Goto H, Iseri K, Hida N. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2024, 39:1016-22. 10.1093\/ndt\/gfad248","journal-title":"Nephrol Dial Transplant"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2014.06.008","article-title":"Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis","volume":"45","author":"Chi H","year":"2014","unstructured":"Chi H, Lin X, Huang H, Zheng X, Li T, Zou Y. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014, 45:469-77. 10.1016\/j.arcmed.2014.06.008","journal-title":"Arch Med Res"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan DM","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, et al.. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019, 73:2961-70. 10.1016\/j.jacc.2019.03.513","journal-title":"J Am Coll Cardiol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.09.019","article-title":"Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials","volume":"34","author":"Ding Y","year":"2015","unstructured":"Ding Y, Li Y, Wen A. Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials. Clin Nutr. 2015, 34:838-44. 10.1016\/j.clnu.2014.09.019","journal-title":"Clin Nutr"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308055","article-title":"Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials","volume":"102","author":"Goldie C","year":"2016","unstructured":"Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart. 2016, 102:198-203. 10.1136\/heartjnl-2015-308055","journal-title":"Heart"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S207-38. 10.2337\/dc25-S010","journal-title":"Diabetes Care"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2019.1644155","article-title":"Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis","volume":"28","author":"Burnier M","year":"2019","unstructured":"Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Blood Press. 2019, 28:358-74. 10.1080\/08037051.2019.1644155","journal-title":"Blood Press"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng J","year":"2014","unstructured":"Cheng J, Zhang W, Zhang X, et al.. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014, 174:773-85. 10.1001\/jamainternmed.2014.348","journal-title":"JAMA Intern Med"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177654","article-title":"Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study","volume":"12","author":"Wu HY","year":"2017","unstructured":"Wu HY, Peng CL, Chen PC, et al.. Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study. PLoS One. 2017, 12:e0177654. 10.1371\/journal.pone.0177654","journal-title":"PLoS One"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S310091","article-title":"Effect of angiotensin receptor blocker and angiotensin converting enzyme inhibitor on kidney function and blood potassium level in Indonesian type 2 diabetes mellitus with hypertension: a three-month cohort study","volume":"14","author":"Puspita FM","year":"2021","unstructured":"Puspita FM, Yunir E, Agustina PS, Sauriasari R. Effect of angiotensin receptor blocker and angiotensin converting enzyme inhibitor on kidney function and blood potassium level in Indonesian type 2 diabetes mellitus with hypertension: a three-month cohort study. Diabetes Metab Syndr Obes. 2021, 14:3841-9. 10.2147\/DMSO.S310091","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12073","article-title":"Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis","volume":"32","author":"Pan G","year":"2014","unstructured":"Pan G, Zhou X, Zhao J. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis. Cardiovasc Ther. 2014, 32:184-8. 10.1111\/1755-5922.12073","journal-title":"Cardiovasc Ther"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-022-01143-7","article-title":"RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus","volume":"42","author":"Kumar V","year":"2022","unstructured":"Kumar V, Agarwal S, Saboo B, Makkar B. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Int J Diabetes Dev Ctries. 2022, 42:576-605. 10.1007\/s13410-022-01143-7","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0365-x","article-title":"A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan","volume":"15","author":"Wu LS","year":"2016","unstructured":"Wu LS, Chang SH, Chang GJ, et al.. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Cardiovasc Diabetol. 2016, 15:56. 10.1186\/s12933-016-0365-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"Wang K","year":"2018","unstructured":"Wang K, Hu J, Luo T, et al.. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018, 43:768-79. 10.1159\/000489913","journal-title":"Kidney Blood Press Res"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0605-7","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials","volume":"18","author":"Liu Y","year":"2017","unstructured":"Liu Y, Ma X, Zheng J, Jia J, Yan T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol. 2017, 18:206. 10.1186\/s12882-017-0605-7","journal-title":"BMC Nephrol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-19-0782","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease - propensity score matching analysis","volume":"84","author":"Kim HJ","year":"2019","unstructured":"Kim HJ, Lee MH, Jo SH, et al.. Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease - propensity score matching analysis. Circ J. 2019, 84:83-90. 10.1253\/circj.CJ-19-0782","journal-title":"Circ J"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16397","article-title":"Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function: a meta-analysis of randomized trials","volume":"77","author":"Sakima A","year":"2021","unstructured":"Sakima A, Arima H, Matayoshi T, Ishida A, Ohya Y. Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function: a meta-analysis of randomized trials. Hypertension. 2021, 77:929-37. 10.1161\/HYPERTENSIONAHA.120.16397","journal-title":"Hypertension"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2015.119","article-title":"Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis","volume":"30","author":"Takahashi S","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016, 30:534-42. 10.1038\/jhh.2015.119","journal-title":"J Hum Hypertens"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110210","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis","volume":"195","author":"Chen Q","year":"2023","unstructured":"Chen Q, Liang Y, Yan J, Du Y, Li M, Chen Z, Zhou J. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2023, 195:110210. 10.1016\/j.diabres.2022.110210","journal-title":"Diabetes Res Clin Pract"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01251-2","article-title":"Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Gu X","year":"2024","unstructured":"Gu X, Jiang S, Yang Y, Li W. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2024, 16:14. 10.1186\/s13098-023-01251-2","journal-title":"Diabetol Metab Syndr"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos G","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021, 143:540-52. 10.1161\/CIRCULATIONAHA.120.051898","journal-title":"Circulation"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1944","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study","volume":"45","author":"Rossing P","year":"2022","unstructured":"Rossing P, Burgess E, Agarwal R, et al.. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. Diabetes Care. 2022, 45:888-97. 10.2337\/dc21-1944","journal-title":"Diabetes Care"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx N","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al.. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44:4043-140. 10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan M","year":"2025","unstructured":"Vaduganathan M, Claggett BL, Kulac IJ, et al.. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation. 2025, 151:149-58. 10.1161\/CIRCULATIONAHA.124.072055","journal-title":"Circulation"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006540","article-title":"Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease","volume":"6","author":"Cooper LB","year":"2017","unstructured":"Cooper LB, Lippmann SJ, Greiner MA, et al.. Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. J Am Heart Assoc. 2017, 6:e006540. 10.1161\/JAHA.117.006540","journal-title":"J Am Heart Assoc"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, et al.. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022, 33:225-37. 10.1681\/ASN.2021070942","journal-title":"J Am Soc Nephrol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova TH","year":"2023","unstructured":"Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023, 22:387-409. 10.1038\/s41573-023-00670-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.034","article-title":"Improving medication adherence in cardiometabolic disease: practical and regulatory implications","volume":"69","author":"Ferdinand KC","year":"2017","unstructured":"Ferdinand KC, Senatore FF, Clayton-Jeter H, et al.. Improving medication adherence in cardiometabolic disease: practical and regulatory implications. J Am Coll Cardiol. 2017, 69:437-51. 10.1016\/j.jacc.2016.11.034","journal-title":"J Am Coll Cardiol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2024.91396","article-title":"Effectiveness of single-tablet combination therapy in improving adherence and persistence and the relation to clinical and economic outcomes","volume":"11","author":"Paoli C","year":"2024","unstructured":"Paoli C, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S. Effectiveness of single-tablet combination therapy in improving adherence and persistence and the relation to clinical and economic outcomes. J Health Econ Outcomes Res. 2024, 11:8-22. 10.36469\/jheor.2024.91396","journal-title":"J Health Econ Outcomes Res"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14228","article-title":"Patient-reported outcomes and treatment adherence in type\u20092 diabetes using natural language processing: wave 8 of the Observational International Diabetes Management Practices Study","volume":"15","author":"Chan JC","year":"2024","unstructured":"Chan JC, Mbanya JC, Chantelot JM, et al.. Patient-reported outcomes and treatment adherence in type\u20092 diabetes using natural language processing: wave 8 of the Observational International Diabetes Management Practices Study. J Diabetes Investig. 2024, 15:1306-16. 10.1111\/jdi.14228","journal-title":"J Diabetes Investig"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2016.11.318","article-title":"Management protocols of stable coronary artery disease in India: executive summary","volume":"68","author":"Mishra S","year":"2016","unstructured":"Mishra S, Ray S, Dalal JJ, et al.. Management protocols of stable coronary artery disease in India: executive summary. Indian Heart J. 2016, 68:868-73. 10.1016\/j.ihj.2016.11.318","journal-title":"Indian Heart J"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S239-51. 10.2337\/dc25-S011","journal-title":"Diabetes Care"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019, 140:e596-646. 10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.61081\/htnj\/23v9i302","article-title":"InSH consensus guideline for the management of hypertension, 2023","volume":"9","author":"Gupta R","year":"2023","unstructured":"Gupta R, Maheshwari A, Verma N, Narasingan SN, Tripathi K, Joshi S, Manoria PC. InSH consensus guideline for the management of hypertension, 2023. Hypertens J. 2023, 9:57-132. 10.61081\/htnj\/23v9i302","journal-title":"Hypertens J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351004-diabetes-kidney-heart-continuum-and-its-implication-on-therapeutic-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:56:15Z","timestamp":1753253775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351004-diabetes-kidney-heart-continuum-and-its-implication-on-therapeutic-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":116,"URL":"https:\/\/doi.org\/10.7759\/cureus.88561","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}